Modulation of the effect of anthracycline efficacy and toxicity by ICRF-187.

[1]  V. Ferrans,et al.  Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. , 1988, The New England journal of medicine.

[2]  M. Green,et al.  Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line. , 1986, Cancer research.

[3]  C. Simone,et al.  Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. , 1982, Biochemistry.

[4]  E. Mimnaugh,et al.  Stimulation by adriamycin of rat heart and liver microsomal NADPH-dependent lipid peroxidation. , 1981, Biochemical pharmacology.

[5]  V. Ferrans,et al.  Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). , 1981, Cancer research.

[6]  N. Bachur,et al.  A general mechanism for microsomal activation of quinone anticancer agents to free radicals. , 1978, Cancer research.

[7]  E. Herman,et al.  Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943). , 1974, Toxicology and applied pharmacology.

[8]  J. Lazo,et al.  Organ Directed Toxicities of Anticancer Drugs , 1988, Developments in Oncology.

[9]  J. Doroshow,et al.  Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. , 1980, The Journal of clinical investigation.